Autologous peripheral blood progenitor cell transplantation in patients with high-risk myelodysplastic syndromes.

Abstract

Most patients with myelodysplastic syndromes (MDSs) who achieve a complete remission under aggressive chemotherapy develop a recurrence within 18 to 24 months. Autologous stem cell transplantation has therefore been suggested as a potential means of increasing treatment efficacy. As compared with bone marrow stem cell autografts, peripheral stem cell autografts have a higher harvesting yield and a shorter duration of aplasia after reinjection. Also, the results reported herein suggest that polyclonal stem cells harvested after chemotherapy-induced aplasia and growth factor therapy are capable of ensuring normal hematopoiesis and may provide prolonged remissions in some patients.

• Authors: G E Verhoef, H Demuynck, M Delforge, P Vandenberghe, J Maertens, P Zachée, M Boogaerts
• Journal: Pathologie-biologie (Pathol Biol (Paris)) Vol. 45 Issue 8 Pg. 651-5 (Oct 1997) ISSN: 0369-8114 [Print] France
• PMID: 9569931 (Publication Type: Journal Article)

Topics

• Adult
• Drug Therapy, Combination
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (therapy)
• Remission Induction (methods)
• Risk Factors